1 Min Read
May 29 (Reuters) - Prescient Therapeutics Ltd
* updates on its clinical trials with PTX-200 following a serious adverse event in a late-stage patient on its breast cancer trial.
* subsequent to preliminary safety and efficacy analyses, last patient enrolled in trial experienced a sae and passed away
* ptx has temporarily paused recruitment to each of its PTX-200 trials
* intends to re-commence enrollment following formal lifting of clinical holds by FDA Source text for Eikon: Further company coverage: